Previous 10 | Next 10 |
2023-12-13 05:20:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food ...
2023-12-12 06:00:00 ET Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) have one big thing in common: They both specialize in the hot area of gene editing, or the repairing of faulty genes responsible for disease. But CRISPR Therapeutics is farther...
2023-12-11 06:44:02 ET Summary The S&P 500 reached 4,600 for the first time since March 2022. The current bull plateau is strong enough to avoid a recession but sluggish enough for the plateau to last for at least 3 years. Cash cows on the bull plateau are helping instant ...
2023-11-29 00:20:22 ET Summary Intellia Therapeutics and CRISPR Therapeutics are considered the top two players in the CRISPR space in the next 1 to 3 years. NTLA focuses on in vivo gene editing and has a comprehensive pipeline targeting various genetic diseases and conditions. ...
2023-11-25 03:39:49 ET Summary Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for its simplicity and versatility. Major publicly ...
2023-11-24 11:31:31 ET More on Intellia Therapeutics Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024 Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript Intellia Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentati...
2023-11-21 15:13:40 ET More on Beam, CRISPR, etc. Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024 Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript) Beam Therapeutics: Sale Of Rights To Verve's In Vivo Ca...
2023-11-16 15:54:01 ET More on CRISPR Therapeutics CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval Risk And Reward: Evaluating Crispr's Exa-Cel For Sickle Cell Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A B...
2023-11-14 17:19:58 ET Summary Intellia Therapeutics, Inc. enrollment completion for the phase 2 study using NTLA-2002 for the treatment of hereditary angioedema is expected in Q4 2023; Results expected in 2024. Pending positive feedback from regulators, potential to initiate a pi...
2023-11-14 08:03:24 ET More on Intellia Therapeutics Intellia Therapeutics, Inc. (NTLA) Q3 2023 Earnings Call Transcript Intellia Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects ...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
2024-07-23 12:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...